Houston、TXにおける骨髄線維症の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、骨髄線維症に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
被験者募集中第3相
- MD Anderson Cancer Center, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
被験者募集中第1相
- The University of Texas, MD Anderson Cancer Center, Houston
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
被験者募集中第3相
- MD Anderson Cancer Center, Houston
- The University of Utah-Huntsman Cancer Institute, Houston
- LUMI Research, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
被験者募集中第1/2相
- MD Anderson, Houston
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
被験者募集中第1相
- MD Anderson Cancer Center, Houston
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
被験者募集中第2相
- MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
被験者募集中第1相
- University of Texas M. D. Anderson Cancer Center, Houston
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
被験者募集中第1/2相
- The University of Texas M. D. Anderson Cancer Center, Houston
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
被験者募集中第2相
- GSK Investigational Site, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
被験者募集中第1相
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
被験者募集中第2相
- MD Anderson, Houston
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
被験者募集中第2相
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
被験者募集中第3相
- U.T. MD Anderson Cancer Center, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
他の都市における骨髄線維症の試験
- New York City, NY18件の研究
- Boston, MA12件の研究
- Durham, NC12件の研究
- Columbus, OH11件の研究
- Seattle, WA11件の研究
- Salt Lake City, UT10件の研究
- Miami, FL10件の研究
- Nashville, TN9件の研究
- Cleveland, OH9件の研究
- Tampa, FL9件の研究
- Atlanta, GA9件の研究
- Baldwin Park, CA9件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。